Study Evaluating AGG-523 in Subjects With Osteoarthritis

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study of the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Subjects With Mild to Moderate Osteoarthritis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00427687

Enrollment

Unknown

Registered

2007-01-29

Start date

2007-02-28

Completion date

2007-06-30

Last updated

2008-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.

Interventions

DRUGAGG-523

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

Inclusion: * Mild to moderate Osteoarthritis of the target knee. * Subjects must be generally healthy but enrolled with stable chronic illness if well controlled.

Design outcomes

Primary

Measure	Time frame
The effect of AGG-523 on biomarkers related to osteoarthritis.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026